Found 6 articles for: "IL-17"
Brodalumab's 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World Evidence
March 2026 | Volume 25 | Issue 3 | Original Article | 211 | Copyright © March 2026
Background: Plaque psoriasis is a chronic immune-mediated disease driven by proinflammatory cytokines. Brodalumab--a recombinant, human monoclonal antibody that functions as an i...
Read MoreReal-World Evidence of Brodalumab Effectiveness for the Treatment of Psoriasis
February 2026 | Volume 25 | Issue 2 | Original Article | 126 | Copyright © February 2026
Brodalumab is a recombinant, fully human monoclonal antibody antagonist of the human interleukin-17 (IL-17) receptor A. It is indicated for the treatment of moderate-to-severe plaque psoriasis in...
Read MoreDual IL-17A/F Blockade for Acrodermatitis Continua of Hallopeau: A Clinical Response to Bimekizumab
February 2026 | Volume 25 | Issue 2 | Case Reports | 172 | Copyright © February 2026
Acrodermatitis continua of Hallopeau (ACH) is a rare, localized variant of pustular psoriasis that primarily affects the distal digits and nail apparatus, often presenting with recurrent pustules...
Read MoreMore Than Skin Clearance: Connecting Brodalumab's Mechanism of Action to Patient Outcomes in Psoriasis
December 2025 | Volume 24 | Issue 12 | Original Article | 1231 | Copyright © December 2025
Psoriasis has profound negative impacts on quality of life (QOL), including stigmatization, discrimination, occupational challenges, and mental health concerns, which are correlated with disease ...
Read MoreNovel Regimen of IL-17A Inhibitor Secukinumab for the Remission of Severe Hidradenitis Suppurativa: Case Report
December 2022 | Volume 21 | Issue 12 | Case Reports | 1358 | Copyright © December 2022
Hidradenitis suppurativa (HS) is a morbid, recurrent skin condition that presents a major challenge to clinical therapy. Investigation into the pathogenesis of HS has implicated local and systemic pro...
Read MoreOnset of Plaque Psoriasis Treatment Responses With Anti-IL-17/IL-23 Biologic Therapies
August 2022 | Volume 21 | Issue 8 | Original Article | 854 | Copyright © August 2022
Background: The impact of psoriasis on quality of life arises from both physical symptoms, such as pain and pruritus, and the psychosocial effects of the often highly visible lesions....
Read More© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
